Treatment with metformin to limit cardiac injury during bypass surgery

• Conditions: coronary artery bypass grafting (CABG); MedDRA version: 13.1Level: LLTClassification code 10006894Term: CABGSystem Organ Class: 10042613 - Surgical and medical procedures; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: EUCTR2011-000099-33-NL
• Lead Sponsor: Radboud University Nijmegen Medical Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-05-04
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

- Acceptation for CABG
- Informed consent
- Age = 18 years

Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 110
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 110

Exclusion Criteria

-Diabetes mellitus
-Renal dysfunction (MDRD < 60 ml/min)
-Elevated liver enzymes (ALAT > 3 times upper limit of reference range)
-Treatment with dipyridamole or xanthine derivatives
-Recent myocardial infarction (<2 weeks before inclusion)

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified